Clinical Trial Results:
            A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 μg once daily) compared with placebo and salmeterol HFA MDI (50 μg twice daily) over 24 weeks in patients with moderate persistent asthma
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2009-018004-18 | 
    Trial protocol  | 
        LV | 
    Global completion date  | 
        
                                    13 Nov 2012
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1(current) | 
    This version publication date  | 
        
                                    16 May 2016
                             
         | 
    
    First version publication date  | 
        
                                    06 May 2015
                             
         | 
    
    Other versions  | 
        |
    Summary report(s)  | 
                                205.418 | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.